CN103356481B - 含有免疫抑制剂的眼用乳剂 - Google Patents
含有免疫抑制剂的眼用乳剂 Download PDFInfo
- Publication number
- CN103356481B CN103356481B CN201310241506.7A CN201310241506A CN103356481B CN 103356481 B CN103356481 B CN 103356481B CN 201310241506 A CN201310241506 A CN 201310241506A CN 103356481 B CN103356481 B CN 103356481B
- Authority
- CN
- China
- Prior art keywords
- emulsion
- weight
- oil
- account
- ophthalmically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Abstract
Description
成分 | EM047 | EM048 | EM049 | EM050 | EM051 | EM052 | EM053 |
CsA | 0.25 | 0.025 | 0.05 | 0.05 | 0.2 | 0.2 | 0.1 |
MCT | 0.75 | 2 | 1 | 2 | 2 | 4 | 2 |
BAK | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 |
四丁酚醛 | 0.12 | 0.3 | 0.16 | 0.3 | 0.3 | 0.3 | 0.3 |
泊洛沙姆 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 |
维生素E | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
甘油 | 2.25 | 2.25 | 2.25 | 2.25 | 2.25 | 2.25 | 2.25 |
纯净水 | qs | qs | qs | qs | qs | qs | qs |
Claims (9)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04292645A EP1655021B1 (en) | 2004-11-09 | 2004-11-09 | Oil-in-water type emulsion with low concentration of cationic agent and positive zeta potential |
EP04292645.1 | 2004-11-09 | ||
US10/991,346 US8298568B2 (en) | 2004-11-09 | 2004-11-18 | Oil-in-water type emulsion with low concentration of cationic agent and positive zeta potential |
US10/991,346 | 2004-11-18 | ||
CNA2005800300698A CN101014317A (zh) | 2004-11-09 | 2005-10-10 | 含有免疫抑制剂的眼用乳剂 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA2005800300698A Division CN101014317A (zh) | 2004-11-09 | 2005-10-10 | 含有免疫抑制剂的眼用乳剂 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103356481A CN103356481A (zh) | 2013-10-23 |
CN103356481B true CN103356481B (zh) | 2017-11-28 |
Family
ID=34931510
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310241506.7A Active CN103356481B (zh) | 2004-11-09 | 2005-10-10 | 含有免疫抑制剂的眼用乳剂 |
CNA2005800300698A Pending CN101014317A (zh) | 2004-11-09 | 2005-10-10 | 含有免疫抑制剂的眼用乳剂 |
CN2005800383296A Active CN101056615B (zh) | 2004-11-09 | 2005-10-10 | 具有稳定正ζ电势的眼用水包油型乳剂 |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA2005800300698A Pending CN101014317A (zh) | 2004-11-09 | 2005-10-10 | 含有免疫抑制剂的眼用乳剂 |
CN2005800383296A Active CN101056615B (zh) | 2004-11-09 | 2005-10-10 | 具有稳定正ζ电势的眼用水包油型乳剂 |
Country Status (14)
Country | Link |
---|---|
US (5) | US8298568B2 (zh) |
EP (1) | EP1655021B1 (zh) |
JP (3) | JP5587936B2 (zh) |
CN (3) | CN103356481B (zh) |
AT (5) | ATE412400T1 (zh) |
DE (5) | DE602004017477D1 (zh) |
DK (1) | DK1809237T3 (zh) |
ES (4) | ES2314354T3 (zh) |
HK (2) | HK1107938A1 (zh) |
IL (3) | IL181446A (zh) |
MX (2) | MX2007005545A (zh) |
NZ (1) | NZ554929A (zh) |
PT (2) | PT1809237E (zh) |
ZA (1) | ZA200703751B (zh) |
Families Citing this family (100)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8232320B2 (en) | 1999-04-28 | 2012-07-31 | The Regents Of The University Of Michigan | Antimicrobial nanoemulsion compositions and methods |
US7767216B2 (en) | 1999-04-28 | 2010-08-03 | The Regents Of The University Of Michigan | Antimicrobial compositions and methods of use |
US7655252B2 (en) | 1999-04-28 | 2010-02-02 | The Regents Of The University Of Michigan | Antimicrobial nanoemulsion compositions and methods |
US20050208083A1 (en) | 2003-06-04 | 2005-09-22 | Nanobio Corporation | Compositions for inactivating pathogenic microorganisms, methods of making the compositons, and methods of use thereof |
DE602004017477D1 (de) * | 2004-11-09 | 2008-12-11 | Novagali Pharma Sa | Öl-in-Wasser-Emulsion mit niedriger Konzentration des kationischen Mittels und positivem Zetapotential |
EP1871349A1 (en) * | 2005-04-11 | 2008-01-02 | Nanobio Corporation | Quaternary ammonium halides for treatment of infectious conditions |
US7297679B2 (en) * | 2005-07-13 | 2007-11-20 | Allergan, Inc. | Cyclosporin compositions |
WO2008051186A2 (en) * | 2005-08-09 | 2008-05-02 | Nanobio Corporation | Nanoemulsion containing compositions having ant i -inflammatory activity |
US7797337B2 (en) * | 2005-09-29 | 2010-09-14 | Scenera Technologies, Llc | Methods, systems, and computer program products for automatically associating data with a resource as metadata based on a characteristic of the resource |
US10137083B2 (en) * | 2006-03-07 | 2018-11-27 | SGN Nanopharma Inc | Ophthalmic preparations |
US11311477B2 (en) | 2006-03-07 | 2022-04-26 | Sgn Nanopharma Inc. | Ophthalmic preparations |
WO2007103294A2 (en) * | 2006-03-07 | 2007-09-13 | Novavax, Inc. | Nanoemulsions of poorly soluble pharmaceutical active ingredients and methods of making the same |
WO2007111806A2 (en) * | 2006-03-23 | 2007-10-04 | Massachusetts Eye And Ear Infirmary | Cyclopentane heptanoic acid compounds for reducing body fat |
US9132071B2 (en) * | 2006-07-28 | 2015-09-15 | Santen Sas | Compositions containing quaternary ammonium compounds |
SI1891939T1 (sl) * | 2006-07-28 | 2013-11-29 | Novagali Pharma S.A. | Sestave vsebujoče kvaternarne amonijeve spojine |
US20080026013A1 (en) * | 2006-07-28 | 2008-01-31 | Laura Rabinovich-Guilatt | Compositions containing quaternary ammonium compounds |
WO2008035246A2 (en) * | 2006-07-28 | 2008-03-27 | Novagali Pharma Sa | Compositions containing quaternary ammonium compounds |
AU2014201978B2 (en) * | 2006-07-28 | 2016-03-10 | Santen Sas | Compositions containing quaternary ammonium compounds |
EP2444829A1 (en) | 2006-09-14 | 2012-04-25 | Carl Zeiss SMT GmbH | Optical element unit and method of supporting an optical element |
EP1938801A1 (en) | 2006-12-22 | 2008-07-02 | Biofrontera Bioscience GmbH | Nanoemulsion |
EP1985298A1 (en) | 2007-04-24 | 2008-10-29 | Azad Pharma AG | Ophtalmic oil-in-water emulsions containing prostaglandins |
WO2008137747A1 (en) | 2007-05-02 | 2008-11-13 | The Regents Of The University Of Michigan | Nanoemulsion therapeutic compositions and methods of using the same |
US20090018057A1 (en) * | 2007-07-09 | 2009-01-15 | Gregory Lambert | OIL IN WATER EMULSION COMPRISING NSAIDs AND QUATERNARY AMMONIUM HALIDES |
US9125807B2 (en) * | 2007-07-09 | 2015-09-08 | Incept Llc | Adhesive hydrogels for ophthalmic drug delivery |
US8512687B2 (en) * | 2007-07-09 | 2013-08-20 | Novagali Pharma Sa | Oil in water emulsion comprising NSAIDs and quaternary ammonium halides |
UA100393C2 (ru) * | 2007-10-16 | 2012-12-25 | Сан Фарма Адвансед Ресьорч Компані Лімітед | Новые офтальмологические композиции |
WO2009063081A2 (en) * | 2007-11-14 | 2009-05-22 | Novagali Pharma Sa | Composition comprising at least one nucleosidic moiety as a therapeutic agent, and ckc. |
US7834172B2 (en) * | 2007-11-14 | 2010-11-16 | Novagali Pharma Sa | Composition comprising at least one nucleosidic moiety as a therapeutic agent, and CKC |
EP2077104A1 (en) * | 2008-01-02 | 2009-07-08 | Novagali Pharma SA | Micellar compositions with ophtalmic applications |
EP2077105A1 (en) * | 2008-01-02 | 2009-07-08 | Novagali Pharma SA | Ophthalmic Micellar Compositions with Enhanced Stability |
EP2127638A1 (en) | 2008-05-30 | 2009-12-02 | Santen Pharmaceutical Co., Ltd | Method and composition for treating ocular hypertension and glaucoma |
RU2504380C2 (ru) * | 2008-09-04 | 2014-01-20 | Сантен Фармасьютикал Ко., Лтд. | АГЕНТ, СПОСОБСТВУЮЩИЙ РОСТУ ВОЛОС, СОДЕРЖАЩИЙ В КАЧЕСТВЕ АКТИВНОГО ИНГРЕДИЕНТА ПРОИЗВОДНОЕ 15,15-ДИФТОРПРОСТАГЛАНДИНА F2α |
WO2010026239A1 (en) * | 2008-09-05 | 2010-03-11 | Ceva Sante Animale Sa | Composition comprising chitosan for ocular administration of vaccine(s) to avians |
WO2010057197A1 (en) | 2008-11-17 | 2010-05-20 | The Regents Of The University Of Michigan | Cancer vaccine compositions and methods of using the same |
CA2750242C (en) | 2009-02-12 | 2018-05-22 | Incept, Llc | Drug delivery through hydrogel plugs |
EP2228057A1 (en) * | 2009-03-04 | 2010-09-15 | Novagali Pharma S.A. | Cationic oil-in-water emulsions containing prostaglandins and uses thereof |
EP2228058A1 (en) | 2009-03-04 | 2010-09-15 | Novagali Pharma S.A. | Anionic oil-in-water emulsion containing prostaglandins and uses thereof |
WO2010135731A1 (en) * | 2009-05-22 | 2010-11-25 | Kaufman Herbert E | Preparations and methods for ameliorating or reducing presbyopia |
US8299079B2 (en) | 2009-05-22 | 2012-10-30 | Kaufman Herbert E | Preparations and methods for ameliorating or reducing presbyopia |
AU2010314863A1 (en) * | 2009-11-09 | 2012-06-14 | Allergan, Inc. | Compositions for enhancing hair growth |
EP2389939A1 (en) | 2010-05-28 | 2011-11-30 | Novagali Pharma S.A. | Use of prostaglandins F2alpha and analogues for the healing of corneal and conjunctival lesions |
US10154923B2 (en) | 2010-07-15 | 2018-12-18 | Eyenovia, Inc. | Drop generating device |
CA2805425C (en) * | 2010-07-15 | 2019-07-23 | Corinthian Ophthalmic, Inc. | Ophthalmic drug delivery |
US10272040B2 (en) | 2010-08-12 | 2019-04-30 | Nanyang Technological University | Liposomal formulation for ocular drug delivery |
US8961501B2 (en) | 2010-09-17 | 2015-02-24 | Incept, Llc | Method for applying flowable hydrogels to a cornea |
EP2982373B1 (en) | 2011-01-19 | 2018-06-13 | Topokine Therapeutics, Inc. | Methods and compostions for reducing body fat |
ES2672238T3 (es) | 2011-01-26 | 2018-06-13 | Allergan, Inc. | Composición androgénica para el tratamiento de una afección oftálmica |
US10307292B2 (en) | 2011-07-18 | 2019-06-04 | Mor Research Applications Ltd | Device for adjusting the intraocular pressure |
US10226417B2 (en) | 2011-09-16 | 2019-03-12 | Peter Jarrett | Drug delivery systems and applications |
EP2779994B1 (en) * | 2011-11-15 | 2020-02-19 | Allergan, Inc. | Suspensions of cyclosporin a form 2 |
AU2012339701B8 (en) | 2011-11-15 | 2017-11-16 | Allergan, Inc. | Autoclavable suspensions of cyclosporin A Form 2 |
WO2013086015A1 (en) | 2011-12-05 | 2013-06-13 | Incept, Llc | Medical organogel processes and compositions |
US8426471B1 (en) | 2011-12-19 | 2013-04-23 | Topokine Therapeutics, Inc. | Methods and compositions for reducing body fat and adipocytes |
WO2013125026A1 (ja) * | 2012-02-24 | 2013-08-29 | ファインバイオメディカル有限会社 | 潤滑性調整液 |
SI2887923T1 (sl) * | 2012-08-24 | 2023-09-29 | Sun Pharmaceutical Industries Limited | Oftalmična formulacija polioksilnega lipida ali polioksilne maščobne kisline in zdravljenje očesnih stanj |
JP6408469B2 (ja) * | 2012-09-06 | 2018-10-17 | ナンヤン テクノロジカル ユニヴァーシティー | ヒアルロン酸をベースとする薬物送達システム |
SG11201600237YA (en) | 2012-11-21 | 2016-02-26 | Topokine Therapeutics Inc | Methods and compositions for locally increasing body fat |
DK2948134T3 (da) | 2013-01-24 | 2020-06-02 | Palvella Therapeutics Inc | Sammensætninger til transdermal indgivelse af mtor-inhibitorer |
CA2939952C (en) | 2013-03-05 | 2022-03-22 | Morgan V. Fedorchak | Thermoresponsive hydrogel containing polymer microparticles for noninvasive ocular drug delivery |
TWI623313B (zh) * | 2013-03-13 | 2018-05-11 | Santen Pharmaceutical Co Ltd | 瞼板腺功能障礙之治療劑 |
US20140275261A1 (en) * | 2013-03-15 | 2014-09-18 | Dr. Reddy's Laboratories, Inc. | Diclofenac parenteral compositions |
RU2513597C1 (ru) * | 2013-04-17 | 2014-04-20 | Федеральное государственное бюджетное учреждение "Научно-исследовательский институт глазных болезней" Российской академии медицинских наук (ФГБУ "НИИГБ" РАМН) | Способ лечения воспалительных состояний переднего отрезка глаза |
NO2753788T3 (zh) | 2013-05-10 | 2018-06-16 | ||
US9820993B2 (en) | 2013-05-15 | 2017-11-21 | Topokine Therapeutics, Inc. | Methods and compositions for topical delivery of prostaglandins to subcutaneous fat |
US9630909B2 (en) | 2013-06-27 | 2017-04-25 | Mylan Laboratories Ltd | Process for the preparation of nepafenac |
US9956195B2 (en) | 2014-01-07 | 2018-05-01 | Nanyang Technological University | Stable liposomal formulations for ocular drug delivery |
RU2016136430A (ru) | 2014-02-11 | 2018-03-15 | Др. Редди'С Лабораторис Лтд. | Парентеральные композиции целекоксиба |
KR102407735B1 (ko) * | 2014-02-14 | 2022-06-10 | 징준 후앙 | 나노에멀젼 전달 시스템의 조성물 |
US20170087096A1 (en) * | 2014-06-13 | 2017-03-30 | Sanofi | Nanocapsular formulation of active pharmaceutical ingredients |
WO2015200425A1 (en) | 2014-06-27 | 2015-12-30 | Topokine Therapeutics, Inc. | Topical dosage regimen |
WO2016100972A2 (en) * | 2014-12-19 | 2016-06-23 | Kemin Industries, Inc. | Intraocular delivery of bioactive molecules using iontophoresis |
US20200237859A1 (en) | 2019-01-25 | 2020-07-30 | Newport Research, Inc. | Aqueous suspensions of cyclosporin |
US11324800B2 (en) | 2015-01-15 | 2022-05-10 | Wellspring Ophthalmics, Inc. | Aqueous suspensions of cyclosporin |
EP3253372B8 (en) * | 2015-02-06 | 2022-06-22 | Woodstock Sterile Solutions, Inc. | Preparation of an oil-in-water emulsion for polymer stabilized pharmaceutical formulations |
CN106176600A (zh) * | 2015-05-07 | 2016-12-07 | 上海现代药物制剂工程研究中心有限公司 | 一种前列地尔冻干微乳剂、原料组合物及其制备方法 |
WO2016182926A1 (en) * | 2015-05-08 | 2016-11-17 | Affinsci Inc. | Preparation of nanoemulsions |
SG11201906729RA (en) | 2016-02-29 | 2019-08-27 | Sun Pharma Global Fze | Topical cyclosporine-containing formulations and uses thereof |
JP6906899B2 (ja) * | 2016-03-30 | 2021-07-21 | 小林製薬株式会社 | 乳化組成物 |
CN109475709B (zh) | 2016-05-03 | 2022-12-27 | 精呼吸股份有限公司 | 使用液滴输送装置生成液滴并将其输送到肺部系统的方法 |
US11395853B2 (en) | 2016-06-23 | 2022-07-26 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Biomimetic drug delivery of an immunomodulatory agent for the treatment of ocular conditions |
EP3266446B1 (en) * | 2016-07-07 | 2018-11-21 | Laboratorios SALVAT, S.A. | Ophthalmic composition comprising castor oil and medium chain triglyceride |
CN106782348A (zh) * | 2017-01-04 | 2017-05-31 | 深圳市华星光电技术有限公司 | 一种led背光驱动电路及液晶显示器 |
US10722499B2 (en) | 2017-01-06 | 2020-07-28 | Palvella Therapeutics, Inc. | Anyhydrous compositions of mTOR inhibitors and methods of use |
US11529476B2 (en) | 2017-05-19 | 2022-12-20 | Pneuma Respiratory, Inc. | Dry powder delivery device and methods of use |
US20200147055A1 (en) * | 2017-05-30 | 2020-05-14 | Eximore Ltd. | Compositions and methods for treating dry eye syndrome delivering antibiotic macrolide |
KR20240034855A (ko) | 2017-06-10 | 2024-03-14 | 아이노비아 인코포레이티드 | 유체를 취급하기 위한, 그리고 눈에 유체를 전달하기 위한 방법들 및 디바이스들 |
JP2020536614A (ja) | 2017-10-04 | 2020-12-17 | ニューマ・リスパイラトリー・インコーポレイテッド | 呼吸により電気的に作動するインライン液滴送達装置および使用方法 |
WO2019079461A1 (en) | 2017-10-17 | 2019-04-25 | Pneuma Respiratory, Inc. | NASAL MEDICATION DELIVERY APPARATUS AND METHODS OF USE |
WO2019089573A1 (en) | 2017-10-30 | 2019-05-09 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Treatment of ocular conditions utilizing a histone/protein deacetylase inhibitor |
JP2021502178A (ja) | 2017-11-08 | 2021-01-28 | ニューマ・リスパイラトリー・インコーポレイテッド | 小容積アンプルを有して呼吸により電気的に作動するインライン液滴送達装置および使用方法 |
CA3092016A1 (en) * | 2018-02-26 | 2020-08-21 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd | Drug delivery systems |
US11000513B2 (en) | 2018-07-02 | 2021-05-11 | Palvella Therapeutics, Inc. | Anhydrous compositions of mTOR inhibitors and methods of use |
CN109010268B (zh) * | 2018-09-28 | 2020-07-10 | 湖北远大天天明制药有限公司 | 一种提高氯霉素稳定性的眼用组合物及其制备方法 |
MX2021006912A (es) | 2018-12-11 | 2021-08-24 | Disruption Labs Inc | Composiciones para la administracion de agentes terapeuticos y metodos de uso y fabricacion de las mismas. |
CN110237233B (zh) * | 2019-07-30 | 2021-01-15 | 沈阳兴齐眼药股份有限公司 | 一种含有环孢素的眼用药物组合物、其制备方法及用途 |
EP4069220A4 (en) * | 2019-12-04 | 2024-04-24 | Restore Vision Llc | OPHTHALMIC FORMULATIONS FOR THE TREATMENT OF PRESBYOPIA |
CN116437909A (zh) * | 2020-06-10 | 2023-07-14 | 迪斯拉普申实验室公司 | 用于递送治疗剂的组合物及其使用方法和制备方法 |
WO2022271848A1 (en) | 2021-06-22 | 2022-12-29 | Pneuma Respiratory, Inc. | Droplet delivery device with push ejection |
CN113577024B (zh) * | 2021-08-20 | 2023-05-05 | 山西利普达医药科技有限公司 | 一种眼用组合物及其制备方法和应用 |
CN116407499A (zh) * | 2021-12-29 | 2023-07-11 | 辅必成(上海)医药科技有限公司 | 一种他克莫司眼用乳剂及其制备方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1149834A (zh) * | 1994-06-01 | 1997-05-14 | 株式会社柳韩洋行 | 含环孢菌素的组合物及其制备方法 |
WO2003053405A1 (en) * | 2001-11-01 | 2003-07-03 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Method and composition for dry eye treatment |
Family Cites Families (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4599353A (en) | 1982-05-03 | 1986-07-08 | The Trustees Of Columbia University In The City Of New York | Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma |
JPH0818989B2 (ja) | 1984-01-12 | 1996-02-28 | 株式会社ミドリ十字 | 脂肪乳剤中のプロスタグランジンの安定化方法 |
US4839342A (en) * | 1987-09-03 | 1989-06-13 | University Of Georgia Research Foundation, Inc. | Method of increasing tear production by topical administration of cyclosporin |
JP2602964B2 (ja) | 1989-10-16 | 1997-04-23 | 裕 水島 | プロスタグランジン類縁体およびその脂肪乳剤 |
IL101241A (en) * | 1992-03-16 | 1997-11-20 | Yissum Res Dev Co | Pharmaceutical or cosmetic composition comprising stabilized oil-in-water type emulsion as carrier |
EP0656779B1 (en) * | 1992-08-28 | 2000-04-12 | Pharmos Corporation | Submicron emulsions as ocular drug delivery vehicles |
IL103907A0 (en) * | 1992-11-27 | 1993-04-04 | Pharmos Corp | Ophthalmic compositions |
US5688819A (en) | 1992-09-21 | 1997-11-18 | Allergan | Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents |
JP3551977B2 (ja) * | 1993-04-08 | 2004-08-11 | ライオン株式会社 | 安定なビタミンa類及びビタミンe類可溶化点眼剤 |
EP0631770B1 (en) * | 1993-06-25 | 1998-07-22 | Alcon Cusi, S.A. | New use of polymeric membranes in the dispensing of pharmaceutical solutions that contain quaternary ammonium compounds as preservatives and corresponding dose dispensor |
US5510383A (en) * | 1993-08-03 | 1996-04-23 | Alcon Laboratories, Inc. | Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension |
ES2094688B1 (es) * | 1994-08-08 | 1997-08-01 | Cusi Lab | Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion. |
US6011062A (en) | 1994-12-22 | 2000-01-04 | Alcon Laboratories, Inc. | Storage-stable prostaglandin compositions |
US5631287A (en) * | 1994-12-22 | 1997-05-20 | Alcon Laboratories, Inc. | Storage-stable prostaglandin compositions |
US5767153A (en) * | 1995-06-07 | 1998-06-16 | Insite Vision Incorporated | Sustained release emulsions |
JP3410364B2 (ja) * | 1997-05-14 | 2003-05-26 | 千寿製薬株式会社 | ジフルプレドナート含有組成物 |
US6114319A (en) | 1997-05-14 | 2000-09-05 | Senju Pharmaceutical Co., Ltd. | Compositions containing difluprednate |
US6066671A (en) * | 1997-12-19 | 2000-05-23 | Alcon Laboratories, Inc. | Treatment of GLC1A glaucoma with 3-benzoyl-phenylacetic acids, esters, or amides |
US6225348B1 (en) * | 1998-08-20 | 2001-05-01 | Alfred W. Paulsen | Method of treating macular degeneration with a prostaglandin derivative |
AU2183900A (en) * | 1998-12-24 | 2000-07-31 | Alcon Laboratories, Inc. | Ep4 receptor agonists for treatment of dry eye |
US20020136771A1 (en) * | 1998-12-31 | 2002-09-26 | Amitee Cosmetics, Inc. | Stabilized ascorbic acid composition |
FR2823441B1 (fr) * | 2001-04-12 | 2004-09-10 | Thea Lab | Composition pharmaceutique a base de macrolides pour application locale en ophtalmologie et son procede de preparation |
EP1418903A2 (en) * | 2001-04-23 | 2004-05-19 | The Board of Regents of the University of Texas System | Prostanoids augment ocular drug penetration |
JP2006512401A (ja) * | 2001-06-05 | 2006-04-13 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | ナノエマルジョンワクチン |
US6872705B2 (en) * | 2001-07-13 | 2005-03-29 | Allergan, Inc. | Use of antimicrobial peptides as preservatives in ophthalmic preparations, including solutions, emulsions, and suspensions |
US6656460B2 (en) * | 2001-11-01 | 2003-12-02 | Yissum Research Development | Method and composition for dry eye treatment |
KR100446960B1 (ko) | 2001-12-04 | 2004-09-01 | 김종국 | 프로스타글란딘 e1을 포함하는 온도감응성 에멀젼 외용제조성물 |
US20030165545A1 (en) * | 2002-01-30 | 2003-09-04 | Allergan, Inc. | Ophthalmic compositions including oil-in-water emulsions, and methods for making and using same |
US20050124699A1 (en) * | 2002-07-02 | 2005-06-09 | Wakamoto Pharmaceutical Co., Ltd. | Drugs for treating or preventing disorders of corneal and/or conjunctival epithelial cells |
WO2004024164A1 (ja) | 2002-08-23 | 2004-03-25 | Santen Pharmaceutical Co., Ltd. | ラタノプロストを有効成分とする安定な点眼液 |
WO2004022063A1 (ja) | 2002-09-09 | 2004-03-18 | Santen Pharmaceutical Co., Ltd. | ラタノプロストを有効成分とする澄明な点眼液 |
US20040115234A1 (en) * | 2002-09-24 | 2004-06-17 | Gewirtz Joan T. | Cosmetic composition |
US7074827B2 (en) * | 2002-10-24 | 2006-07-11 | Sucampo Ag (Usa) Inc. | Method for treating ocular hypertension and glaucoma |
JP4361294B2 (ja) * | 2003-02-25 | 2009-11-11 | ロート製薬株式会社 | ケトチフェン含有組成物 |
JP4694773B2 (ja) * | 2003-06-06 | 2011-06-08 | ロート製薬株式会社 | 粘膜適用液状組成物 |
US20050059583A1 (en) * | 2003-09-15 | 2005-03-17 | Allergan, Inc. | Methods of providing therapeutic effects using cyclosporin components |
JP5382972B2 (ja) * | 2003-12-26 | 2014-01-08 | ロート製薬株式会社 | 粘度低下が防止された組成物 |
US20050175651A1 (en) * | 2004-01-09 | 2005-08-11 | L'oreal | Aqueous dispersion of nanocapsules with an oily core |
EP1611879B1 (en) | 2004-07-02 | 2009-08-12 | Novagali Pharma SA | Use of emulsions for intra- and periocular injection |
JP4999304B2 (ja) * | 2004-09-27 | 2012-08-15 | ロート製薬株式会社 | ヒアルロン酸又はその塩を含有する粘膜適用組成物 |
DE602004017477D1 (de) * | 2004-11-09 | 2008-12-11 | Novagali Pharma Sa | Öl-in-Wasser-Emulsion mit niedriger Konzentration des kationischen Mittels und positivem Zetapotential |
CA2586074C (en) * | 2004-11-09 | 2013-07-23 | Novagali Pharma Sa | Ophthalmic oil-in-water type emulsion with stable positive zeta potential |
US20090170944A1 (en) * | 2008-01-02 | 2009-07-02 | Novagali Pharma Sa | Ophthalmic micellar compositions with enhanced stability |
US20090169629A1 (en) * | 2008-01-02 | 2009-07-02 | Novagali Pharma Sa | Micellar compositions with ophthalmic applications |
BRPI0912302A2 (pt) * | 2008-05-28 | 2015-10-20 | Alcon Res Ltd | emulsões autopreservados |
EP2228057A1 (en) * | 2009-03-04 | 2010-09-15 | Novagali Pharma S.A. | Cationic oil-in-water emulsions containing prostaglandins and uses thereof |
EP2228058A1 (en) * | 2009-03-04 | 2010-09-15 | Novagali Pharma S.A. | Anionic oil-in-water emulsion containing prostaglandins and uses thereof |
EP2389939A1 (en) * | 2010-05-28 | 2011-11-30 | Novagali Pharma S.A. | Use of prostaglandins F2alpha and analogues for the healing of corneal and conjunctival lesions |
-
2004
- 2004-11-09 DE DE602004017477T patent/DE602004017477D1/de active Active
- 2004-11-09 AT AT04292645T patent/ATE412400T1/de not_active IP Right Cessation
- 2004-11-09 ES ES04292645T patent/ES2314354T3/es active Active
- 2004-11-09 EP EP04292645A patent/EP1655021B1/en active Active
- 2004-11-18 US US10/991,346 patent/US8298568B2/en active Active
-
2005
- 2005-10-10 AT AT05800012T patent/ATE415942T1/de not_active IP Right Cessation
- 2005-10-10 DE DE602005011480T patent/DE602005011480D1/de active Active
- 2005-10-10 MX MX2007005545A patent/MX2007005545A/es active IP Right Grant
- 2005-10-10 DK DK05795930T patent/DK1809237T3/da active
- 2005-10-10 ES ES05795930T patent/ES2320574T3/es active Active
- 2005-10-10 MX MX2007003045A patent/MX2007003045A/es active IP Right Grant
- 2005-10-10 CN CN201310241506.7A patent/CN103356481B/zh active Active
- 2005-10-10 PT PT05795930T patent/PT1809237E/pt unknown
- 2005-10-10 PT PT05802097T patent/PT1809238E/pt unknown
- 2005-10-10 US US11/667,129 patent/US8273362B2/en active Active
- 2005-10-10 ZA ZA200703751A patent/ZA200703751B/xx unknown
- 2005-10-10 DE DE602005026464T patent/DE602005026464D1/de active Active
- 2005-10-10 DE DE602005010733T patent/DE602005010733D1/de active Active
- 2005-10-10 US US11/667,355 patent/US8372434B2/en active Active
- 2005-10-10 AT AT08102553T patent/ATE498392T1/de not_active IP Right Cessation
- 2005-10-10 ES ES05802097T patent/ES2317319T3/es active Active
- 2005-10-10 AT AT05802097T patent/ATE412401T1/de not_active IP Right Cessation
- 2005-10-10 ES ES05800012T patent/ES2319129T3/es active Active
- 2005-10-10 US US11/665,066 patent/US8298569B2/en active Active
- 2005-10-10 CN CNA2005800300698A patent/CN101014317A/zh active Pending
- 2005-10-10 DE DE602005012136T patent/DE602005012136D1/de active Active
- 2005-10-10 CN CN2005800383296A patent/CN101056615B/zh active Active
- 2005-10-10 AT AT05795930T patent/ATE418964T1/de not_active IP Right Cessation
- 2005-10-10 NZ NZ554929A patent/NZ554929A/en unknown
-
2006
- 2006-10-10 US US12/089,609 patent/US20080268020A1/en not_active Abandoned
-
2007
- 2007-02-20 IL IL181446A patent/IL181446A/en active IP Right Grant
- 2007-05-01 IL IL182897A patent/IL182897A/en unknown
-
2008
- 2008-01-21 HK HK08100777.1A patent/HK1107938A1/xx unknown
- 2008-03-27 IL IL190497A patent/IL190497A/en active IP Right Grant
- 2008-06-17 HK HK08106646.7A patent/HK1112411A1/xx unknown
-
2012
- 2012-04-05 JP JP2012086806A patent/JP5587936B2/ja active Active
- 2012-05-15 JP JP2012111941A patent/JP5773941B2/ja active Active
-
2014
- 2014-02-19 JP JP2014029816A patent/JP5894202B2/ja active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1149834A (zh) * | 1994-06-01 | 1997-05-14 | 株式会社柳韩洋行 | 含环孢菌素的组合物及其制备方法 |
WO2003053405A1 (en) * | 2001-11-01 | 2003-07-03 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Method and composition for dry eye treatment |
Non-Patent Citations (1)
Title |
---|
The potential of lipid emulsion for ocular delivery of lipophilic drugs;Shunmugaperumal Tamilvanan etal;《European Journal of Pharmaceutics and Biopharmaceutics》;20040601;第58卷;第357–368页 * |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103356481B (zh) | 含有免疫抑制剂的眼用乳剂 | |
Singh et al. | Therapeutic nanoemulsions in ophthalmic drug administration: Concept in formulations and characterization techniques for ocular drug delivery | |
CA2578176C (en) | Ophthalmic emulsions containing an immunosuppressive agent | |
Gawin-Mikołajewicz et al. | Ophthalmic nanoemulsions: From composition to technological processes and quality control | |
Choradiya et al. | A comprehensive review on nanoemulsion as an ophthalmic drug delivery system | |
Jacob et al. | Lipid nanoparticles as a promising drug delivery carrier for topical ocular therapy—an overview on recent advances | |
Kalam et al. | Delivery of gatifloxacin using microemulsion as vehicle: formulation, evaluation, transcorneal permeation and aqueous humor drug determination | |
Pathak et al. | Design and development of a novel pH triggered nanoemulsified in-situ ophthalmic gel of fluconazole: ex-vivo transcorneal permeation, corneal toxicity and irritation testing | |
CN104302308B (zh) | 含有环孢菌素的无刺激性的纳米乳剂眼用组合物 | |
Cardoso et al. | In situ gelling microemulsion for topical ocular delivery of moxifloxacin and betamethasone | |
Gore et al. | Ocular emulsions and dry eye: a case study of a non-biological complex drug product delivered to a complex organ to treat a complex disease | |
Nayak et al. | PEGylated microemulsion for dexamethasone delivery to posterior segment of eye | |
Gohil et al. | Optimization of brinzolamide loaded microemulsion using formulation by design approach: characterization and in-vitro evaluation | |
CN106692052B (zh) | 一种环孢素眼用乳剂组合物 | |
Renukuntla et al. | Advances in in-vitro bioequivalence testing methods for complex ophthalmic generic products | |
AU2012202829B2 (en) | Ophthalmic emulsions containing an immunosuppressive agent | |
Mehetre et al. | Rationalized approach for formulation and optimization of ebastine microemulsion using design expert for solubility enhancement | |
Chaudhary et al. | Role of nanoemulsion as drugs delivery systems in opthalmology: A Comprehensive review | |
Joshi et al. | Optimization and characterization of lipid based nano emulsion of prednisolone acetate for ophthalmic drug delivery | |
Bodkhe et al. | Ophthalmic Microemulsion: Formulation Design and Process Optimization | |
Wang et al. | Tacrolimus-Loaded Cationic Nanoemulsion In-Situ Gel System: In-Vitro Characterization and Performance in a Dry-Eye Rabbit Model | |
Saettone et al. | Ophthalmic emulsions and suspensions | |
Attia et al. | Prednisolone loaded-cationic nanoemulsion formulation for uveitis management | |
Ruchake et al. | DESIGN OPTIMIZATION AND EVALUATION OPHTHALMIC NANOEMULSION | |
Göttel | In situ gelling nanofibers: an innovative strategy for the treatment of keratomycosis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C53 | Correction of patent of invention or patent application | ||
CB02 | Change of applicant information |
Address after: The Mayan city of France Applicant after: Samtian Simple Co.,Ltd. Address before: The Mayan city of France Applicant before: Nova Scotia drug Limited by Share Ltd. Address after: The Mayan city of France Applicant after: Nova Scotia drug Limited by Share Ltd. Address before: The Mayan city of France Applicant before: NOVAGALI PHARMA S.A. |
|
COR | Change of bibliographic data |
Free format text: CORRECT: APPLICANT; FROM: NOVAGALI PHARMA SA TO: NUOWA JIALI DRUGS EASY CO., LTD. Free format text: CORRECT: APPLICANT; FROM: NUOWA JIALI DRUGS EASY CO., LTD. TO: SANTEN SIMPLE CO., LTD. |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1189163 Country of ref document: HK |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1189163 Country of ref document: HK |